ASH 2024 | Early findings from the CAR-PRISM trial of cilta-cel in high-risk smoldering myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses early findings on the safety and efficacy of CAR T-cell therapy in high-risk smoldering myeloma. She highlights the promising results of the CAR-PRISM (NCT05767359) study using ciltacabtagene autoleucel (cilta-cel), which show that the treatment can induce complete remission and measurable residual disease (MRD) negativity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So again, building on the same idea that high-risk smoldering myeloma is the best time to use your best immunotherapy. And cilta-cel is one of those, a CAR-T therapy, where it’s basically one and done. You’re using your own T-cells, engineering them again, giving them to your patient, and leaving them alone. And indeed, we’re showing the first six patients, so it’s very early...
So again, building on the same idea that high-risk smoldering myeloma is the best time to use your best immunotherapy. And cilta-cel is one of those, a CAR-T therapy, where it’s basically one and done. You’re using your own T-cells, engineering them again, giving them to your patient, and leaving them alone. And indeed, we’re showing the first six patients, so it’s very early. It’s just proof of concept that we can do that safely in our patients. And we’re showing the first six patients now with many of them already at one year of follow-up, MRD negative, complete remission, and doing very well. Again, this is very early. We’re not saying that people should be doing that. But we’re hoping that this will be expanded. And we’re hoping that this will be one of the options that we can offer our patients in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Oncopeptides: Consultancy; GlaxoSmithKline: Consultancy; Vor Biopharma: Other: Speaker fees; Regeneron: Consultancy, Other: Speaker fees; AbbVie: Consultancy; Binding Site, part of Thermo Fisher Scientific: Consultancy; Huron Consulting: Consultancy; Takeda: Consultancy, Other: Speaker fees; Sanofi: Consultancy; Novartis: Consultancy; 10X Genomics: Consultancy; Bristol Myers Squibb: Consultancy, Other: Speaker fees; Pfizer: Consultancy, Other: Speaker fees; Standard Biotools: Other: Speaker fees; Window Therapeutics: Consultancy; Menarini Silicon Biosystems: Consultancy, Other: Speaker fees; Aptitude Health: Consultancy; CurioScience: Consultancy, Other: Speaker fees; Adaptive: Consultancy; Janssen: Consultancy, Other: Speaker fees; Amgen: Consultancy, Other: Speaker fees; PreDICTA Bioscience: Consultancy, Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees, Other: Co-founder; Disc Medicine: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees.
